Trial Search Results

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: General Electric

Stanford Investigator(s):


  • Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Positron Emission Tomography
  • Device: Investigational software and coils in PET/MR scan


Phase 1/Phase 2


Inclusion Criteria:

   - ER+ breast cancer at initial diagnosis prior to surgery or at recurrence (at least one
   ER+ lesion based on results of biopsy).

   - Able to provide written consent

   - Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group
   (ECOG)/World Health Organization (WHO) equivalent)

Exclusion Criteria:

   - Less than 18 years-old at the time of radiotracer administration

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance

   - Renal function impairment preventing administration of MRI contrast

   - Metallic implants (contraindicated for MRI)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Marcellus
Not Recruiting